Skip to main content

Table 1 Demographic Table: This will include all the following information in both Enoxaparin and Rivaroxaban Arm

From: Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre

VariablesEnoxaparin
80 (53.3%)
Rivaroxaban
70 (46.7%)
p-value
Baseline Demographics
Age in years48.67 ± 14.4551.84 ± 13.490.17
Gender  0.25
Male37 (46.2%)39 (55.7%) 
Female43 (53.8%)31 (44.3%) 
BMI23.63 ± 4.6425.20 ± 5.430.05
Baseline Co-Morbids
Coronary Artery Disease  1.00
No79 (98.8%)69 (98.6%) 
Yes1 (1.2%)1 (1.4%) 
Hypertension  0.30
No70 (87.5%)57 (81.4%) 
Yes10 (12.5%)13 (18.6%) 
Diabetes Mellitus  0.49
No64 (80.0%)59 (84.3%) 
Yes16 (20.0%)11 (15.7%) 
Creatinine Clearance  0.78
Less than 608 (10.0%)8 (11.4%) 
Equal or above 6072 (90.0%)62 (88.6%) 
Baseline Malignancy History
Active Cancer  0.58
No9 (11.2%)6 (8.6%) 
Yes71 (88.8%)64 (91.4%) 
Cancer Type  0.07
GI23 (28.8%)18 (26.1%) 
Breast9 (11.2%)17 (24.6%) 
GU21 (26.2%)22 (31.9%) 
Lungs4 (5.0%)3 (4.3%) 
Misc.23 (28.8%)9 (13.0%) 
Disease status  0.89
Non-metastatic42 (52.5%)36 (51.4%) 
Metastatic38 (47.5%)34 (48.6%) 
Chemotherapy  0.82
No30 (37.5%)25 (35.7%) 
Yes50 (62.5%)45 (64.3%) 
Baseline Laboratory Findings
Hemoglobin Level10.65 ± 2.1913.12 ± 14.210.13
Platelet Level274.93 ± 140.70302.60 ± 153.840.25
Leukocyte Count9.67 ± 4.968.16 ± 3.790.04
Albumin3.46 ± 0.783.75 ± 0.560.01
Creatinine0.81 ± 0.640.73 ± 0.270.34
Creatinine clearance128.02 ± 82.76114.30 ± 45.650.22